Olcay Ünver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olcay Ünver has a total of 333 co-authors. Here are the top co-authors by number of shared publications:
- Dilşad Türkdoğan
Department of Pediatric Neurology, Marmara University Faculty of Medicine, Pendik Training and Research Hospital, Istanbul, Türkiye
13 shared publications - Gülten Öztürk
Marmara University Pendik Training and Research Hospital, Department of Pediatric Neurology, Istanbul, Turkey
6 shared publications - Almala Pinar Ergenekon
Division of Pediatric Pulmonology, Marmara University School of Medicine, İstanbul, Türkiye
4 shared publications - Ela Erdem Eralp
Division of Pediatric Pulmonology Marmara University School of Medicine Istanbul Turkey
4 shared publications - Sermin Özcan
Adiyaman University Training and Research Hospital, Department of Pediatric Neurology, Adiyaman, Turkey
4 shared publications - Yasemin Gokdemir
Division of Pediatric Pulmonology, Marmara University School of Medicine, İstanbul, Türkiye
4 shared publications
Latest Publications
- Open Access
Climate-Smart Irrigation: Multiple Perspectives for Better Decision-Making
Climate-smart irrigation (CSI) links agricultural productivity and livelihoods with adaptation, resilience, and, where feasible, mitigation. Assessing CSI is complicated by the different purposes of irrigation decisions and the scales at which their consequences emerge. This focused integrative review distinguishes actors from the decision perspectives through which success is judged. It identifies six non-hierarchical perspectives: user/livelihood, service/operational, resource stewardship/allocation, public policy/societal, public/development investment, and commercial/market. Three decision situations illustrate their interactions. Irrigation efficiency may benefit farmers without increasing basin water availability; solar-powered irrigation may reduce operational emissions while changing groundwater-use incentives; and scarcity allocation involves competing needs, rights, and resource risks. These situations show why success in one decision context does not necessarily indicate climate-smart performance. The review examines the boundaries and strength of supporting evidence, distinguishing demonstrated outcomes from indirect evidence and enabling conditions. The six perspectives are not criteria that every irrigation decision must satisfy. Their value lies in revealing dependencies, consequences, and evidence beyond the immediate decision position. CSI can therefore be assessed more clearly by examining what irrigation decisions achieve, for whom, under what conditions, at what scale, and with what climate relevance.
Open AccessClimate-Smart Irrigation: Multiple Perspectives for Better Decision-Making
Climate-smart irrigation (CSI) links agricultural productivity and livelihoods with adaptation, resilience, and, where feasible, mitigation. Assessing CSI is complicated by the different purposes of irrigation decisions and the scales at which their consequences emerge. This focused integrative review distinguishes actors from the decision perspectives through which success is judged. It identifies six non-hierarchical perspectives: user/livelihood, service/operational, resource stewardship/allocation, public policy/societal, public/development investment, and commercial/market. Three decision situations illustrate their interactions. Irrigation efficiency may benefit farmers without increasing basin water availability; solar-powered irrigation may reduce operational emissions while changing groundwater-use incentives; and scarcity allocation involves competing needs, rights, and resource risks. These situations show why success in one decision context does not necessarily indicate climate-smart performance. The review examines the boundaries and strength of supporting evidence, distinguishing demonstrated outcomes from indirect evidence and enabling conditions. The six perspectives are not criteria that every irrigation decision must satisfy. Their value lies in revealing dependencies, consequences, and evidence beyond the immediate decision position. CSI can therefore be assessed more clearly by examining what irrigation decisions achieve, for whom, under what conditions, at what scale, and with what climate relevance.
- Open Access
- 20 October 2026
- Published by MDPI AG in Preprints.org
Climate-Smart Irrigation: Multiple Perspectives for Better Decision-Making
Climate-smart irrigation (CSI) brings productivity and livelihoods together with adaptation, resilience and, where feasible, mitigation. Judging whether irrigation is climate-smart is complicated by the different purposes of irrigation decisions and the scales at which their consequences become visible. This focused integrative review distinguishes actors from the decision perspectives through which success is judged. It examines six non-hierarchical perspectives: user/livelihood, service/operational, resource stewardship/allocation, public-policy/societal, public/development investment, and commercial/market. Three decision situations illustrate their interactions. Improved irrigation efficiency may benefit farmers without increasing basin water availability; solar irrigation may reduce operational emissions while changing groundwater-use incentives; and scarcity allocation brings competing needs, rights and resource risks into the same decision. These situations demonstrate why success within one decision context does not necessarily establish climate-smart performance. The review examines the scale and boundaries of supporting evidence and distinguishes demonstrated outcomes from indirect evidence and enabling conditions. The six perspectives are not criteria every irrigation decision must satisfy. Their value lies in revealing when a decision depends on consequences, conditions or evidence outside the immediate decision position. CSI can be judged more clearly through what irrigation decisions achieve, for whom, under what conditions, at what scale and with what climate relevance.
- 20 October 2026
- Published by MDPI AG in Preprints.org
Open AccessClimate-Smart Irrigation: Multiple Perspectives for Better Decision-Making
Climate-smart irrigation (CSI) brings productivity and livelihoods together with adaptation, resilience and, where feasible, mitigation. Judging whether irrigation is climate-smart is complicated by the different purposes of irrigation decisions and the scales at which their consequences become visible. This focused integrative review distinguishes actors from the decision perspectives through which success is judged. It examines six non-hierarchical perspectives: user/livelihood, service/operational, resource stewardship/allocation, public-policy/societal, public/development investment, and commercial/market. Three decision situations illustrate their interactions. Improved irrigation efficiency may benefit farmers without increasing basin water availability; solar irrigation may reduce operational emissions while changing groundwater-use incentives; and scarcity allocation brings competing needs, rights and resource risks into the same decision. These situations demonstrate why success within one decision context does not necessarily establish climate-smart performance. The review examines the scale and boundaries of supporting evidence and distinguishes demonstrated outcomes from indirect evidence and enabling conditions. The six perspectives are not criteria every irrigation decision must satisfy. Their value lies in revealing when a decision depends on consequences, conditions or evidence outside the immediate decision position. CSI can be judged more clearly through what irrigation decisions achieve, for whom, under what conditions, at what scale and with what climate relevance.
- Open Access
Balancing Competing Demands for Sustainable Water Development
With increasing demand for water and declining water availability, the imperative to manage water and balance competing needs has become more important than ever
Open AccessBalancing Competing Demands for Sustainable Water Development
With increasing demand for water and declining water availability, the imperative to manage water and balance competing needs has become more important than ever
- Open Access
- 31 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A rapid LNA-PCR assay from blood lysate without DNA purification for the diagnosis of homozygous SMN1 deletion in spinal muscular atrophy
- 31 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA rapid LNA-PCR assay from blood lysate without DNA purification for the diagnosis of homozygous SMN1 deletion in spinal muscular atrophy
- Open Access
- 21 August 2026
- Published by The International Child Neurology Association in Journal of the International Child Neurology Association
- Vol. 1 (1)
Spinal muscular atrophy: history and current treatment landscape
In recent years, pediatric neurology has witnessed significant advances in the development of disease-modifying therapies, with spinal muscular atrophy (SMA) emerging as one of the most impactful conditions in this field. This article provides a comprehensive overview of the history of SMA, highlighting its evolving classification and the genetic basis underlying its clinical variability. Moreover, it outlines the development and clinical trial data of the three Food and Drug Administration- and European Medicines Agency-approved therapies: nusinersen, onasemnogene abeparvovec, and risdiplam. These treatments have shifted SMA from a fatal diagnosis to a treatable condition, especially when initiated presymptomatically. Finally, the article discusses future directions, including combination therapies, novel pharmacological targets, biomarker development, and the need for ethical and equitable access to treatment worldwide. With ongoing research, SMA continues to serve as a paradigm for progress in neuromuscular medicine and the potential of personalized, gene-targeted therapies.
- 21 August 2026
- Published by The International Child Neurology Association in Journal of the International Child Neurology Association
- Vol. 1 (1)
Open AccessSpinal muscular atrophy: history and current treatment landscape
In recent years, pediatric neurology has witnessed significant advances in the development of disease-modifying therapies, with spinal muscular atrophy (SMA) emerging as one of the most impactful conditions in this field. This article provides a comprehensive overview of the history of SMA, highlighting its evolving classification and the genetic basis underlying its clinical variability. Moreover, it outlines the development and clinical trial data of the three Food and Drug Administration- and European Medicines Agency-approved therapies: nusinersen, onasemnogene abeparvovec, and risdiplam. These treatments have shifted SMA from a fatal diagnosis to a treatable condition, especially when initiated presymptomatically. Finally, the article discusses future directions, including combination therapies, novel pharmacological targets, biomarker development, and the need for ethical and equitable access to treatment worldwide. With ongoing research, SMA continues to serve as a paradigm for progress in neuromuscular medicine and the potential of personalized, gene-targeted therapies.
- 30 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 139, 101-109
Neonatal-onset genetic epilepsies: Insights from a large multicentre cohort
- 30 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 139, 101-109
Neonatal-onset genetic epilepsies: Insights from a large multicentre cohort
- 28 October 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 268-274
Cardiac safety of low-dose ACTH therapy in infantile spasms: Evidence from electrocardiography and advanced echocardiography
- 28 October 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 268-274
Cardiac safety of low-dose ACTH therapy in infantile spasms: Evidence from electrocardiography and advanced echocardiography
- Open Access
Personalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.
Open AccessPersonalized Management and Timing of Thymectomy in Juvenile Myasthenia Gravis: Insights from Routine Clinical Scale Use in a Single-Center Retrospective Cohort—A Case Series
Introduction: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with a variable clinical course and limited pediatric-specific treatment guidelines. Objective clinical scales, such as the Quantitative Myasthenia Gravis (QMG) Score and the Pediatric Myasthenia Gravis Quality of Life 15 (PM-QOL15), may support individualized management, but their role in routine practice remains underexplored. Methods: We retrospectively reviewed 10 seropositive JMG patients followed at a single tertiary neuromuscular clinic between 2014 and 2024. All patients underwent a systematic assessment with QMG at each visit, while PM-QOL15 was administered at the final visit. Clinical data, comorbidities, antibody status, treatment modalities, and outcomes were analyzed. Associations between treatment strategies, comorbidities, and scale scores were explored using appropriate statistical methods. Results: Seven patients (70%) underwent thymectomy, resulting in a reduction in mean QMG scores from 7.7 to 2.4, though residual relapses were observed. Chronic intravenous immunoglobulin (IVIG) therapy, administered to 70% of patients, did not significantly reduce relapse rates or steroid exposure and was associated with higher QMG scores in the second year, suggesting use in more severe phenotypes rather than therapeutic efficacy. Prolonged corticosteroid therapy did not improve remission time or relapse frequency and was complicated by major adverse effects in two patients. Timing of azathioprine initiation showed no significant correlation with relapse frequency. PM-QOL15 correlated strongly with mean QMG (r = 0.88, p < 0.001), reflecting cumulative disease burden. Patients with comorbidities required longer stabilization, although differences were not statistically significant. Conclusions: The routine integration of QMG and PM-QOL15 into follow-up may facilitate the earlier recognition of subclinical deterioration, provide objective measures of treatment response, and guide personalized management in JMG. Thymectomy showed benefit in selected patients, while the long-term roles of IVIG and corticosteroids remain uncertain. Larger multicenter prospective studies are warranted to confirm these findings and refine evidence-based strategies for pediatric JMG.
- 29 April 2025
- Published by Academician Publishing
- p. 729-732
Bazal Ganglionların Heredodejeneratif Hastalıkları ve Görüntüleme Bulguları
- 29 April 2025
- Published by Academician Publishing
- p. 729-732
Bazal Ganglionların Heredodejeneratif Hastalıkları ve Görüntüleme Bulguları
- 29 April 2025
- Published by Academician Publishing
- p. 713-728
Serebellum ve Beyin Sapının Heredodejeneratif Hastalıkları ve Görüntüleme Bulguları
- 29 April 2025
- Published by Academician Publishing
- p. 713-728
Serebellum ve Beyin Sapının Heredodejeneratif Hastalıkları ve Görüntüleme Bulguları